Factors associated with long-term opioid therapy discontinuation for people with chronic non-cancer pain in UK primary care: a population-based retrospective cohort study

英国基层医疗机构慢性非癌性疼痛患者长期阿片类药物治疗中断的相关因素:一项基于人群的回顾性队列研究

阅读:5

Abstract

BACKGROUND: Understanding the characteristics linked to long-term opioid therapy (L-TOT) discontinuation may inform safer and personalised discontinuation strategies. This study aimed to identify factors associated with L-TOT discontinuation in people with chronic non-cancer pain (CNCP) in UK primary care. METHODS: A retrospective cohort study using the Clinical Practice Research Datalink Aurum data (2000-2020) was conducted. Adults with CNCP receiving L-TOT (three or more opioid prescriptions within 90 days or ≥90 days' supply within the first year, excluding the first 30 days) were included. Discontinuation was defined as opioid-free for ≥180 days after an L-TOT. Mixed-effects logistic models with a random intercept for general practice were used to identify sociodemographic, comorbidities, lifestyle, and pharmacological factors associated with L-TOT discontinuation. RESULTS: Among 573 639 L-TOT users, 5.2% (n=29 589) discontinued within the first year. Discontinuation was more likely among Asians (adjusted odds ratio [aOR], 1.31; 95% confidence interval [CI], 1.23-1.39; P<0.001), Blacks (aOR, 1.21; 95% CI, 1.13-1.31; P<0.001), non-smokers (aOR, 1.09; 95% CI, 1.05-1.12; P<0.001), those living in the least deprived area (aOR, 1.09; 95% CI, 1.04-1.14; P<0.001), those using weak and short-acting opioids (aOR, 1.50; 95% CI, 1.39-1.61), those with co-existing osteoarthritis (aOR, 1.06; 95% CI, 1.02-1.11; P=0.003), those with anxiety (aOR, 1.04; 95% CI, 1.01-1.07; P=0.003), or those co-using non-steroidal anti-inflammatory drugs (aOR, 1.06; 95% CI, 1.03-1.09; P<0.001) or benzodiazepines (aOR, 1.08; 95% CI, 1.05-1.11; P<0.001). CONCLUSIONS: This study identified key characteristics of people with chronic non-cancer pain who are more likely to discontinue long-term opioid therapy. This may help to inform the development of tailored interventions to promote safe opioid discontinuation in primary care.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。